Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates.
clinical research / practice
desensitization
kidney transplantation / nephrology
kidney transplantation: living donor
translational research / science
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
27
05
2021
received:
04
01
2021
accepted:
27
05
2021
pubmed:
4
6
2021
medline:
1
2
2022
entrez:
3
6
2021
Statut:
ppublish
Résumé
Kidney transplant candidates (KTCs) who are HLA highly sensitized (calculated panel-reactive alloantibodies >95%) have poor access to deceased kidney transplantation. In this single-center prospective study, 13 highly sensitized desensitization-naïve KTCs received IV tocilizumab (8 mg/kg) every 4 weeks. We evaluated tolerability as well as immune responses, that is, T cell, B cell, T follicular helper (Tfh) subsets, blood cytokines (IL-6, soluble IL-6 receptor-sIL-6R-, IL-21), blood chemokines (CXCL10, CXCL13), and anti-HLA alloantibodies. Tocilizumab treatment was well-tolerated except in one patient who presented spondylodiscitis, raising a note of caution. Regarding immune parameters, there were no significant changes of percentages of lymphocyte subsets, that is, CD3
Identifiants
pubmed: 34080291
doi: 10.1111/ajt.16709
pii: S1600-6135(22)08043-1
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-84Informations de copyright
© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Ingsathit A, Kamanamool N, Thakkinstian A, Sumethkul V. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation. 2013;95(7):943-948. https://doi.org/10.1097/TP.0b013e3182848de2
Schold JD, Buccini LD, Goldfarb DA, Flechner SM, Poggio ED, Sehgal AR. Association between kidney transplant center performance and the survival benefit of transplantation versus dialysis. Clin J Am Soc Nephrol. 2014;9(10):1773-1780. https://doi.org/10.2215/CJN.02380314
Cassuto J, Babu S, Laskowski I. The survival benefit of kidney transplantation in the setting of combined peripheral arterial disease and end-stage renal failure. Clin Transplant. 2016;30(5):545-555. https://doi.org/10.1111/ctr.12720
Haller MC, Kammer M, Oberbauer R. Dialysis vintage and outcomes in renal transplantation. Nephrol Dial Transplant. 2019;34(4):555-560. https://doi.org/10.1093/ndt/gfy099
Malvezzi P, Jouve T, Noble J, Rostaing L. Desensitization in the Setting of HLA-Incompatible Kidney Transplant. Exp Clin Transplant. 2018;16(4):367-375. https://doi.org/10.6002/ect.2017.0355
Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365(4):318-326. https://doi.org/10.1056/NEJMoa1012376
Kahwaji J, Jordan SC, Najjar R, et al. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab. Transpl Int. 2016;29(12):1276-1285. https://doi.org/10.1111/tri.12832
Klein K, Süsal C, Schäfer SM, et al. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl. 2013;14(1):199-202. https://doi.org/10.1016/j.atherosclerosissup.2012.10.030
Rostaing L, Maggioni S, Hecht C, et al. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates. Exp Clin Transplant. 2015;13(Suppl 1):165-169.
Kauke T, Klimaschewski S, Schoenermarck U, et al. Outcome after desensitization in HLA or ABO-incompatible kidney transplant recipients: a single center experience. PLoS One. 2016;11(1):e0146075. https://doi.org/10.1371/journal.pone.0146075
Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99(11):2356-2363. https://doi.org/10.1097/TP.0000000000000741
Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377(5):442-453. https://doi.org/10.1056/NEJMoa1612567
Rostaing LPE, Malvezzi P. HLA-incompatible kidney transplantation-worth the risk? N Engl J Med. 2016;374(10):982-984. https://doi.org/10.1056/NEJMe1601379
Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant. 2014;14(7):1573-1580. https://doi.org/10.1111/ajt.12786
Scott LJ. Tocilizumab: a review in rheumatoid arthritis. Drugs. 2017;77(17):1865-1879. https://doi.org/10.1007/s40265-017-0829-7
Mahmood Z, Muhammad K, Schmalzing M, Roll P, Dörner T, Tony H-P. CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis Res Ther. 2015;17:61. https://doi.org/10.1186/s13075-015-0580-y
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542-552. https://doi.org/10.1002/art.27221
Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63(5):1255-1264. https://doi.org/10.1002/art.30242
Chavele K-M, Merry E, Ehrenstein MR. Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production. J Immunol. 2015;194(6):2482-2485. https://doi.org/10.4049/jimmunol.1401190
Wu G, Chai N, Kim I, Klein AS, Jordan SC. Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. Transpl Immunol. 2013;28(2-3):138-143. https://doi.org/10.1016/j.trim.2013.03.003
Daligault M, Bardy B, Noble J, et al. Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates. Transplant Direct. 2021;7(5):e690. https://doi.org/10.1097/TXD.0000000000001139
Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456-464. https://doi.org/10.1136/annrheumdis-2018-214367
Sethi S, Peng A, Najjar R, Vo A, Jordan SC, Huang E. Infectious complications in tocilizumab-treated kidney transplant recipients. Transplantation. 2021. https://doi.org/10.1097/TP.0000000000003512
Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258-267. https://doi.org/10.1080/14397595.2018.1546357
Doberer K, Duerr M, Halloran PF, et al. A Randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32(3):708-722. https://doi.org/10.1681/ASN.2020071106
Shirota Y, Yarboro C, Fischer R, Pham T-H, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118-128. https://doi.org/10.1136/annrheumdis-2012-201310
Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2013;23(4):827-831. https://doi.org/10.1007/s10165-012-0715-9
Pesce B, Soto L, Sabugo F, et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol. 2013;171(3):237-242. https://doi.org/10.1111/cei.12017
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-3964. https://doi.org/10.1182/blood-2008-05-155846
Kim SJ, Lee K, Diamond B. Follicular helper T cells in systemic lupus erythematosus. Front Immunol. 2018;9:1793. https://doi.org/10.3389/fimmu.2018.01793
Bao Y-Q, Wang J-P, Dai Z-W, et al. Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2020;39(1):281-290. https://doi.org/10.1007/s10067-019-04775-z
Elmoselhi H, Mansell H, Soliman M, Shoker A. Circulating chemokine ligand levels before and after successful kidney transplantation. J Inflamm (Lond). 2016;13:32. https://doi.org/10.1186/s12950-016-0141-4
Shin B-H, Everly MJ, Zhang H, et al. Impact of Tocilizumab (Anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation. 2020;104(4):856-863. https://doi.org/10.1097/TP.0000000000002895
Lavacca A, Presta R, Gai C, et al. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant. 2020;34(8):e13908. https://doi.org/10.1111/ctr.13908